In his current role as a full-time clinician, he regularly performs coronary angiography and angioplasty (including pressure wire assessment, intracoronary imaging (IVUS and OCT) and complex intervention), right heart catheterisation for assessment of pulmonary hypertension and catheter-directed thrombolysis for the management of pulmonary embolism. He is also fully accredited in cardiac MRI with a specialist interest in imaging for assessment of coronary artery disease and effects of Covid-19 on the heart.

Dr Kotecha is friendly, approachable and passionate about holistic patient care. He takes the time to complete a comprehensive assessment and is keen to involve patients in a fully informed decision-making process.

• Royal College of Physicians (UK)
• British Cardiac Society (BCS)
• British Cardiovascular Intervention Society (BCIS)
• European Society of Cardiology (ESC)
• European Association of Cardiovascular Imaging (EACVI)

1. Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance. Kotecha T, Knight DS, Razvi Y, et al. Eur Heart J 2021;42(19):1866-1878.
2. The evolution of cardiovascular COVID-19 research. Kotecha T, Knight DS, Moon JC, Cole GD, Fontana M. Eur Heart J 2021;42(30):2953-2954.
3. Quantitative cardiovascular magnetic resonance myocardial perfusion mapping to assess hyperaemic response to adenosine stress. Kotecha T, Monteagudo JM, Martinez-Naharro A, et al. Eur Heart J Cardiovasc Imaging 2021;22(3):273-281.
4. Assessment of multivessel coronary artery disease using cardiovascular magnetic resonance pixelwise quantitative perfusion mapping. Kotecha T, Chacko L, Chehab O, et al. JACC Cardiovasc Imaging 2020 13(12):2546-2557.Ongoing exercise intolerance following COVID-19: A magnetic resonance-augmented cardiopulmonary exercise test study. Brown JT, Saigal A, Karia N…… Kotecha T, et al. J Am Heart Assoc 2022;11(9):e024207.
5. Invasive coronary physiology in patients with angina and non-obstructive coronary artery disease: a consensus document from the coronary microvascular dysfunction workstream of the British Heart Foundation/National Institute of Health Research Partnership. UK Coronary Microvascular Dysfunction Working Group. Heart 2022.
6. Automated pixel-wise quantitative myocardial perfusion mapping by CMR to detect obstructive coronary artery disease and coronary microvascular dysfunction: validation against invasive coronary microvascular dysfunction. Kotecha T, Martinez-Naharro A, Boldrini M, et al. JACC Cardiovasc Imaging 2019;12(10):1958-69.
7. Acute changes in cardiac structural and tissue characterization parameters following haemodialysis measured using cardiovascular magnetic resonance. Kotecha T, Martinez-Naharro A, Yoowannakul S, et al. Sci Rep 2019;9(1):1388.
8. Myocardial edema and prognosis in amyloidosis. Kotecha T, Martinez-Naharro A, Treibel T, et al. J Am Coll Cardiol 2018;71(25):2919-31.
9. Reduced exercise capacity in patients with systemic sclerosis is associated with lower peak tissue oxygen extraction: a cardiovascular magnetic resonance-augmented cardiopulmonary exercise study. Brown JT, Kotecha T, Steeden JA, et al. J Cardiovasc Magn Reson 2021;23(1):118
10. Cardiac magnetic resonance-derived extracellular volume mapping for the quantification of hepatic and splenic amyloid. Chacko L, Boldrini M, Martone R, Law S, Martinez-Naharro A, Hutt DF, Kotecha T, et al. Circ Cardiovasc Imaging 2021;CIRCIMAGING121012506.
11. Myocardial perfusion imaging after severe COVID-19 infection demonstrates regional ischemia rather than global blood flow reduction. Thornton GD, Shetye A, Knight DS,……Kotecha T, et al. Front Cardiovasc Med 2021;8:764599.
12. Effect of remote ischaemic conditioning on infarct size and remodeling in ST-segment elevation myocardial infarction patients: the CONDI-2/ERIC-PPCI CMR substudy. Francis R, Chong J, Ramlall,…..Kotecha T, et al. Basic Res Cardiol 2021;116(1):59.
13. COVID-19: Myocardial injury in survivors. Knight DS, Kotecha T, Razvi Y, et al. Circulation 2020;142:1120-1122.
14. COVID-19 pandemic and STEMI: pathway activation and outcomes from the pan-London heart attack group. Little CD, Kotecha T, Candilio L, et al. Open Heart 2020;7(2):e001432.
15. Automated inline analysis of myocardial perfusion MRI with deep learning. Xue H, Davies RH, Brown LAE, Knott KD, Kotecha T, et al. Radiol Artif Intell 2020;2(6):e200009.
16. Rationale and design of the Medical Research Council’s precision medicine with Zibotentan in microvascular angina (PRIZE) trial. Morrow AJ, Ford TJ, Mangion K, Kotecha T, et al. Am Heart J 2020;229:70-80.
17. Rescue valve-in-valve-in-valve TAVR for acute transvalvular aortic regurgitation. Malik IS, Jabbour RJ, Ruparelia N, Sen S, Hadjizoulou N, Rana B, Chukwuemeka AO, Gopalan D, Kotecha T, Mikhail GW. Cardiovasc Revasc Med 2020;21(11S):11-13.
18. Automated detection of left ventricle in arterial input function images for inline perfusion mapping using deep learning: A study of 15,000 patients. Xue H, Tseng E, Knott KD, Kotecha T, et al. Magn Reson Med 2020;84(5):2788-2800.
19. Haemodialysis patients with less extracellular water overload and smaller cardiac atrial chamber sizes are at greater risk of a fall in blood pressure during dialysis. Yoowannakul S, Vongsanim S, Kotecha T, et al. Ther Apher Dial 2021;25(1):16-23.
20. Myocardial edema, myocyte injury, and disease severity in Fabry Disease. Augusto JB, Nordin S, Vijapurapu R, Baig S, Bulluck Hm Castelletti S, Alfarih M, Knott K, Captur G, Kotecha T, et al. Circ Cardiovasc Imaging 2020;13(3):e010171.
21. Reply: Amyloidosis in the Era of Mass Spectrometry-Based Proteomics. Kotecha T, Martinez-Naharro A, Gillmore JD, Hawkins PN, Fontana M. J Am Coll Cardiol 2018;72(15):1881
22. The prognostic Significance of Quantitative Myocardial Perfusion: An Artificial Intelligence Base Approach Using Perfusion Mapping. Knott KD, Seraphim A, Augusto JB, Xue H, Chacko L, Aung N, Petersen SE, Cooper JA, Manisty C, Bhuva AN, Kotecha T, et al. Circulation 2020 (Epub ahead of print).
23. Cardiovascular magnetic resonance-guided right heart catheterization in a conventional CMR environment – predictors of procedure success and duration in pulmonary artery hypertension. Knight DS, Kotecha T, Martinex-Naharro A, Brown JT, Bertelli M, Fontana M, Muthurangu V, Coghlan JG. J Cardiovasc Mag Reson 2019;21(1):57.
24. Non-contrast Magnetic Resonance for the Diagnosis of Cardiac Amyloidosis. Baggiano A, Boldrini M, Martinez-Naharro A, Kotecha T, et al. JACC Cardiovasc Imaging 2019 (Epub ahead of print)
25. Interrogation of the infarcted and salvaged myocardium using multiparametric mapping cardiovascular magnetic resonance in reperfused ST-segment elevation myocardial infarction patients. Hausenloy DJ, Lim MX, Chan MHH, Paradies V, Francis R, Kotecha T, et al. Sci Rep 2019;9(1):9056.
26. Effect of remote ischaemic conditioning on clinical outcomes in pateints with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomized controlled trial. Hausenloy D, Kharbanda RK, Moller UK, et al (collaborator). Lancet 2019 (Epub ahead of print)
27. Native T1 and Extracellular Volume in Transthyretin Amyloidosis. Martinez-Naharro A, Kotecha T, Norrington K, et al. JACC Cardiovasc Imaging 2018 (Epub ahead of print)
28. Cardiac structural and functional consequences of amyloid deposition by cardiac magnetic resonance and echocardiography and their prognostic roles. Knight DS, Zumbo G, Barcella W, Steeden JA, Muthurangu V, Kotecha T, et al. JACC Cardiovasc Imaging 2018 (Epub ahead of print)
29. Acute coronary syndromes. Kotecha T, Rakhit RD. Clin Med (London) 2016;16(Suppl 6):s43-48
30. Rational testing: Investigating suspected heart failure. Kotecha T, Fox KF. BMJ 2013;346:f2442
31. Physiological versus pathological left ventricular hypertrophy. Kotecha T, Fox KF. Heart Metab 2012;56:3-7
32. Magnetic Resonance in Transthyretin Cardiac Amyloidosis. Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, Kotecha T, et al. J Am Coll Cardiol 2017; 25;70(4):466-477.
33. Prospective comparison of novel dark blood late gadolinium enhancement with conventional bright blood imaging for the detection of scar. Francis R, Kellman P, Kotecha T, et al. J Cardiovasc Magn Reson 2017;19(1):91
34. Full left ventricular coverage is essential for the accurate quantification of the area-at-risk by T1 and T2 mapping. Bulluck H, Bryant JA, Lim MX, Tan XW, Ramlall M, Francis R, Kotecha T, et al. Sci Rep 2017;7(1):4871.
35. Prevalence and outcomes of coronary artery perforation during percutaneous coronary intervention. Guttmann OP, Jones DA, Gulati A, Kotecha T, et al. EuroIntervention 2017;13(5):e595-e601
36. Superior long-term outcome associated with native vessel versus graft vessel PCI following secondary PCI in patients with prior CABG. Mavroudis C, Kotecha T, Chehab O, et al. Int J Cardiol 2017;228:563-569
37. Microparticles and their role in coronary artery disease. Koganti S, Eleftheriou D, Brogan PA, Kotecha T, et al. Int J Cardiol 2017;230:339-345
38. Reducing time to angiography and hospital stay for patients with high-risk non-ST-elevation acute coronary syndromes: retrospective analysis of a paramedic-activated direct access pathway. Koganti S, Patel N, Kotecha T, et al. BMJ Open 2016;6(6):e010428
39. Choice of intracoronary imaging: When to use intravascular ultrasound or optical coherence tomography. Koganti S, Kotecha T, Rakhit R. Radcliffe Cardiology 2016;11(1):ePub date: 25 March 2016
40. A new method for applying randomized control study data to the individual patient: A novel quantitative patient-centered approach to interpreting composite end points. Ahmad Y, Nijjer S, Cook CM, Kotecha T et al. Int J Cardiol 2015:195:216-24
41. Cardiac Rehabilitation. Thomas RJ, Myat A, Kotecha T, Squires RW. In: Myat A, Gerschlick A (eds). Landmark Papers in Cardiovascular Medicine. Oxford University Press 2012; p457-480